Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, DC, United States.
Front Immunol. 2018 Aug 14;9:1861. doi: 10.3389/fimmu.2018.01861. eCollection 2018.
Tissue-resident memory T (T) cells provide first-line defense against invading pathogens encountered at barrier sites. In the lungs, T cells protect against respiratory infections, but wane more quickly than T cells in other tissues. This lack of a sustained T population in the lung parenchyma explains, at least in part, why infections with some pathogens, such as influenza virus and respiratory syncytial virus (RSV), recur throughout life. Intranasal (IN) vaccination with a murine cytomegalovirus (MCMV) vector expressing the M protein of RSV (MCMV-M) has been shown to elicit robust populations of CD8 T cells that accumulate over time and mediate early viral clearance. To extend this finding, we compared the inflationary CD8 T cell population elicited by MCMV-M vaccination with a conventional CD8 T cell population elicited by an MCMV vector expressing the M2 protein of RSV (MCMV-M2). Vaccination with MCMV-M2 induced a population of M2-specific CD8 T cells that waned rapidly, akin to the M2-specific CD8 T cell population elicited by infection with RSV. In contrast to the natural immunodominance profile, however, coadministration of MCMV-M and MCMV-M2 did not suppress the M-specific CD8 T cell response, suggesting that progressive expansion was driven by continuous antigen presentation, irrespective of the competitive or regulatory effects of M2-specific CD8 T cells. Moreover, effective viral clearance mediated by M-specific CD8 T cells was not affected by the coinduction of M2-specific CD8 T cells. These data show that memory inflation is required for the maintenance of CD8 T cells in the lungs after IN vaccination with MCMV.
组织驻留记忆 T(T)细胞为第一道防线,抵御屏障部位遇到的入侵病原体。在肺部,T 细胞可抵抗呼吸道感染,但比其他组织中的 T 细胞更快衰减。肺部实质中缺乏持续的 T 群体至少部分解释了为什么某些病原体(如流感病毒和呼吸道合胞病毒(RSV))的感染会终生复发。用表达 RSV M 蛋白的鼠巨细胞病毒(MCMV)载体进行鼻内(IN)接种已被证明可引发大量的 CD8 T 细胞,这些细胞会随着时间的推移而积累并介导早期病毒清除。为了扩展这一发现,我们比较了 MCMV-M 疫苗接种引发的膨胀性 CD8 T 细胞群体与表达 RSV M2 蛋白的 MCMV 载体引发的常规 CD8 T 细胞群体。用 MCMV-M2 疫苗接种可诱导迅速衰减的 M2 特异性 CD8 T 细胞群体,类似于 RSV 感染引发的 M2 特异性 CD8 T 细胞群体。然而,与自然免疫优势谱相反,共施用 MCMV-M 和 MCMV-M2 并未抑制 M 特异性 CD8 T 细胞反应,这表明渐进性扩张是由持续的抗原呈递驱动的,而与 M2 特异性 CD8 T 细胞的竞争或调节作用无关。此外,M 特异性 CD8 T 细胞介导的有效病毒清除不受 M2 特异性 CD8 T 细胞共诱导的影响。这些数据表明,在用 MCMV 进行 IN 接种后,记忆膨胀是肺部 CD8 T 细胞维持所必需的。